Bivalirudin Is a Dual Inhibitor of Thrombin and Collagen-Dependent Platelet Activation in Patients Undergoing Percutaneous Coronary Intervention | Zendy

Carey Kimmelstiel | Zendy; Ping Zhang | Zendy; Navin K. Kapur | Zendy; Andrew Weintraub | Zendy; Barath Krishnamurthy | Zendy; Vilma Castaneda | Zendy; Lidija Covic | Zendy; Athan Kuliopulos | Zendy

Open Access

Bivalirudin Is a Dual Inhibitor of Thrombin and Collagen-Dependent Platelet Activation in Patients Undergoing Percutaneous Coronary Intervention

Author(s) -

Carey Kimmelstiel,

Ping Zhang,

Navin K. Kapur,

Andrew Weintraub,

Barath Krishnamurthy,

Vilma Castaneda,

Lidija Covic,

Athan Kuliopulos

Publication year - 2011

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.110.959098

Subject(s) - bivalirudin , thrombin , conventional pci , medicine , direct thrombin inhibitor , platelet , percutaneous coronary intervention , platelet activation , pharmacology , cardiology , myocardial infarction , atrial fibrillation , dabigatran , warfarin

Bivalirudin, a direct thrombin inhibitor, is a widely used adjunctive therapy in patients undergoing percutaneous intervention (PCI). Thrombin is a highly potent agonist of platelets and activates the protease-activated receptors, PAR1 and PAR4, but it is not known whether bivalirudin exerts antiplatelet effects in PCI patients. We tested the hypothesis that bivalirudin acts as an antiplatelet agent in PCI patients by preventing activation of PARs on the platelet surface.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research